Cover Image
市場調查報告書

胰管腺癌 : 開發平台分析

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257834
出版日期 內容資訊 英文 250 Pages
訂單完成後即時交付
價格
Back to Top
胰管腺癌 : 開發平台分析 Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 250 Pages
簡介

胰管腺癌,是侵襲胰臟的惡性腫瘤。可觀察到腹上部痛擴散到背部、皮膚發黃、黃疸、食慾不振、體重減少、憂鬱症、血栓等症狀。原因有抽煙、酒精成癮(酒精中毒)、肥胖、家族病史、年齡、慢性胰炎、糖尿病等。治療包含化療、放射線治療等。

本報告提供胰管腺癌的治療藥的開發情形調查分析、開發中產品的概要、臨床實驗的各階段的產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

胰管腺癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • AbbVie Inc.
  • BerGenBio AS
  • Clovis Oncology, Inc.
  • Coare Biotechnology, Inc.
  • FibroGen, Inc.
  • Gilead Sciences, Inc.
  • Immodulon Therapeutics Ltd.
  • Immunomedics, Inc.
  • Incuron, LLC
  • Merck & Co., Inc.
  • Nerviano Medical Sciences S.r.l.
  • OncoMed Pharmaceuticals, Inc.
  • Sillajen Biotherapeutics
  • Tara Immuno-Oncology Therapeutics LLC
  • Tokai Pharmaceuticals, Inc.

治療藥的評估

  • 單獨療法的情況
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BGB-324
  • CBL-0137
  • CBT-1111
  • CBT-3112
  • demcizumab
  • FG-3019
  • galeterone
  • Hu-5F9G4
  • ibrutinib
  • idelalisib
  • IMM-101
  • ipafricept
  • JX-929
  • MK-0752
  • MK-8628
  • momelotinib dihydrochloride
  • MRK-003
  • NMSP-715
  • 胰管腺癌治療用IDO1阻礙寡核甘酸
  • PSL-001
  • rucaparib phosphate
  • sacituzumab
  • SBP-101
  • siG12D-LODER
  • 胰管腺癌治療用Wnt信號、eIF5A 阻礙小分子
  • 胰管腺癌治療用GLT-1調整小分子
  • vantictumab

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8532IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016, provides an overview of the Pancreatic Ductal Adenocarcinoma (Oncology) pipeline landscape.

Pancreatic ductal adenocarcinoma is a malignant neoplasm that affects pancreas. Symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression, blood clots. Predisposing factors include smoking, alcohol abuse, obesity, family history, age, chronic pancreatitis and diabetes. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Ductal Adenocarcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 15, 1 and 15 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Pancreatic Ductal Adenocarcinoma.

Pancreatic Ductal Adenocarcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatic Ductal Adenocarcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatic Ductal Adenocarcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Ductal Adenocarcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatic Ductal Adenocarcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Pancreatic Ductal Adenocarcinoma Overview
  • Therapeutics Development
  • Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies
  • Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes
  • Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance
  • Pancreatic Ductal Adenocarcinoma - Products under Development by Companies
  • Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes
  • Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development
  • Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment
  • Drug Profiles
  • Pancreatic Ductal Adenocarcinoma - Dormant Projects
  • Pancreatic Ductal Adenocarcinoma - Discontinued Products
  • Pancreatic Ductal Adenocarcinoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2016
  • Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by BerGenBio AS, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by BioNTech AG, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Celgene Corporation, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Clovis Oncology, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by COARE Biotechnology, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Concordia International Corp, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Eli Lilly and Company, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by FibroGen, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Gilead Sciences, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Halozyme Therapeutics, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Immodulon Therapeutics Ltd., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Immunomedics, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Incuron, LLC, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Incyte Corporation, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Inflection Biosciences Limited, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by InvivoGen Therapeutics, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by MedImmune, LLC, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Merck & Co., Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Novartis AG, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Oryx GmbH & Co. KG, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Pfizer Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Quest PharmaTech Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Soricimed Biopharma Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Sun BioPharma, Inc., H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Swedish Orphan Biovitrum AB, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Pipeline by Tokai Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Dormant Projects, H2 2016
  • Pancreatic Ductal Adenocarcinoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2016
  • Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top